DK1419177T3 - Rensningsproces til fremstilling i stor skala af Gc-globulin og produkt tilvejebragt ved anvendelse af den samt deres anvendelse indenfor medicin - Google Patents

Rensningsproces til fremstilling i stor skala af Gc-globulin og produkt tilvejebragt ved anvendelse af den samt deres anvendelse indenfor medicin

Info

Publication number
DK1419177T3
DK1419177T3 DK02754557T DK02754557T DK1419177T3 DK 1419177 T3 DK1419177 T3 DK 1419177T3 DK 02754557 T DK02754557 T DK 02754557T DK 02754557 T DK02754557 T DK 02754557T DK 1419177 T3 DK1419177 T3 DK 1419177T3
Authority
DK
Denmark
Prior art keywords
globulin
medicine
scale production
purification process
product
Prior art date
Application number
DK02754557T
Other languages
Danish (da)
English (en)
Inventor
Inga Laursen
Gunnar Houen
Charlotte Svaerke Jorgensen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of DK1419177T3 publication Critical patent/DK1419177T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK02754557T 2001-08-14 2002-08-12 Rensningsproces til fremstilling i stor skala af Gc-globulin og produkt tilvejebragt ved anvendelse af den samt deres anvendelse indenfor medicin DK1419177T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101217 2001-08-14
PCT/DK2002/000531 WO2003016348A2 (en) 2001-08-14 2002-08-12 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine

Publications (1)

Publication Number Publication Date
DK1419177T3 true DK1419177T3 (da) 2008-08-25

Family

ID=8160667

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02754557T DK1419177T3 (da) 2001-08-14 2002-08-12 Rensningsproces til fremstilling i stor skala af Gc-globulin og produkt tilvejebragt ved anvendelse af den samt deres anvendelse indenfor medicin

Country Status (9)

Country Link
EP (1) EP1419177B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005508892A (cg-RX-API-DMAC7.html)
AT (1) ATE393780T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002321012B2 (cg-RX-API-DMAC7.html)
CA (1) CA2456843A1 (cg-RX-API-DMAC7.html)
DE (1) DE60226327T2 (cg-RX-API-DMAC7.html)
DK (1) DK1419177T3 (cg-RX-API-DMAC7.html)
ES (1) ES2305272T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003016348A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5112060B2 (ja) * 2004-06-29 2013-01-09 リライアンス ライフ サイエンシーズ プライベイト リミテッド ウイルス安全性生物学的流体の調製のための方法
CN100354301C (zh) * 2005-10-13 2007-12-12 南京工业大学 化学合成多肽的新型大规模分离制备技术
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
EP2571892A2 (en) * 2010-05-18 2013-03-27 AbbVie Inc. Apparatus and process of purification of proteins
EP2612921B1 (en) 2010-09-03 2016-11-02 Morita Pharmaceutical Ind., Ltd. Method for production of novel degalactosylated gc globulin
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
WO2015087981A1 (ja) * 2013-12-13 2015-06-18 医療法人再生未来 ウシ初乳酵素処理物、その製造方法、組成物および飲食品
EP3131589B1 (en) * 2014-04-15 2023-05-17 Boehringer Ingelheim International GmbH Method and use for continuously inactivating a virus during manufacture of a biological product
PL3290043T3 (pl) * 2015-06-01 2023-07-03 Saisei Pharma Co., Ltd. Produkt mleczny poddany obróbce enzymatycznej, sposób jego wytwarzania, kompozycja i produkt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
AU663050B2 (en) * 1990-04-11 1995-09-28 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds
US6268478B1 (en) * 1996-02-12 2001-07-31 Cedars-Sinai Medical Center Intracellular vitamin D binding protein

Also Published As

Publication number Publication date
CA2456843A1 (en) 2003-02-27
DE60226327T2 (de) 2009-07-09
WO2003016348A2 (en) 2003-02-27
ATE393780T1 (de) 2008-05-15
EP1419177B1 (en) 2008-04-30
DE60226327D1 (de) 2008-06-12
EP1419177A2 (en) 2004-05-19
AU2002321012B2 (en) 2008-07-24
JP2005508892A (ja) 2005-04-07
ES2305272T3 (es) 2008-11-01
WO2003016348A3 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
DE602004030369D1 (de) Therapieverfahren
DK1419177T3 (da) Rensningsproces til fremstilling i stor skala af Gc-globulin og produkt tilvejebragt ved anvendelse af den samt deres anvendelse indenfor medicin
WO2005103687A3 (en) System and method for providing optimal concentrations for medication infusions
Chen et al. Adjustable parameters and the effectiveness of adjunct robot-assisted gait training in individuals with chronic stroke
Rothenburg et al. COVID-19 antibody donation using immunoadsorption: report of two cases
Liu et al. Intravenous Administration of Vitamin C in the Treatment of Herpes Zoster‐Associated Pain: Two Case Reports and Literature Review
Zhang et al. Electroacupuncture promotes nerve regeneration and functional recovery in rats with spinal cord contusion through the coordinate interaction of CD4 and BDNF
Di Sarno et al. Intranasal Human-Recombinant Nerve Growth Factor Enhances Motor and Cognitive Function Recovery in a Child with Severe Traumatic Brain Injury
CN202776947U (zh) 一种带储液瓶的刮板装置
Makhovskaya et al. Postural disorders of neurological genesis in elderly patients: pathogenesis and features of diagnostics (literature review)
CN106511528A (zh) 一种皱皮木瓜提取物、组合物及用途
DK2037949T3 (da) Fremgangsmåde til at fremstille et "transfer-faktor" medikament
CN104560925A (zh) 一种从人凝血因子ⅸ层析废液中激活制备人凝血酶的方法
Vrielink Considerations on the number of plasma donations per donor per year: Con
Kang et al. Experimental studies of validation and stability of sweet bee venom using HPLC
Habib et al. Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001)
CN103451256A (zh) S-腺苷甲硫氨酸的制备方法
Hansen Passion for vascular disease research yields $5 million in NIH funding for Yabing Chen
Bourget et al. Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Circumstances
Cheng et al. A Novel pH Dependent C5 Monoclonal Antibody with Better Developability
CN101204577A (zh) 一种a型肉毒毒素结晶复合物的制备方法
RU2489172C1 (ru) Способ проведения лечебного дискретного плазмафереза с экстракарпоральной модификацией эритроцитов и лейкоцитов индукторами интерферона, антиоксидантами и протекторами клеток
Waller et al. Direct Oral Anticoagulants Reduce Hypercoagulopathy and Preserve Podocyte Function in an Experimental Model of Glomerular Disease
Ivanova et al. Therapeutic benefit of PRP-therapy in treatment of atrophic vaginitis and vulva lichen sclerosus
Penberthy Nutrition for Health